血液疾患の薬と診断の世界市場

Report Highlights

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

Report Ovewview

Report Scope
This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.
The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.
The growing number of individuals with leukemia is the main reason for the market’s growth and the development of more effective drugs.
Report Includes
– 49 data tables and 44 additional tables
– An overview of the current and future global markets for drugs and diagnostics for hematological disorders
– Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
– Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
– Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
– A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
– Review of technological developments, product introductions, and other recent industry activity of the major players
– Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
– An analysis of recent patents
– A look at the competitive landscape, including companies’ market shares, M&A activity and venture funding
– Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Table of Contents

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

PESTEL Analysis

Political

Economic

Social

Technological

Environmental

Legal

Porter’s Five Forces Analysis

Bargaining Power of Buyers

Bargaining Power of Suppliers

Potential of New Entrants

Threat of Substitutes

Competition in the Industry

Supply Chain and Logistics for Hematological Instruments

Chapter 3 Market Dynamics

Market Drivers

Incidence of Blood Disorders

Rising Use of Automation

Diagnosis of Hematology Disorders

Increasing Government and Private Funding for Treatment

Market Restraints

High Cost of Instruments

High Cost of Treatment

Reimbursement Challenges for Physicians

Market Opportunities

Rising Health Awareness

Emerging Economies

Chapter 4 Patent Landscape and Current Developments in Drugs

Patent Landscape

New Approvals

Chapter 5 Emerging Technologies and Developments

Overview

Emerging Technologies

AI-Assisted Diagnosis

Next-Generation Sequencing (NGS)

Microfluidics and Lab-on-a-Chip Devices

Gene Therapies

Immunotherapies

Clinical Trials

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown

Segmentation by Market

Hematological Disorders Diagnostics Market

Hematological Disorders Diagnostic Market, By Product Type

Hematological Disorders Diagnostic Market, By End User

Hematology Drug Market

Hematology Drug Market, By Drug Type

Geographic Breakdown

North America

Europe

Asia-Pacific

Rest of the World

Chapter 7 Competitive Intelligence

Leading Companies

Hematological Disorder Diagnostics

Hematological Disorder Drugs

New Developers of Drugs for Rare Hematology Disorders

Chapter 8 Appendix

Methodology

Sources

Abbreviations

Company Profiles

ABBOTT

AMGEN INC.

BIO-RAD LABORATORIES INC.

BRISTOL MYERS SQUIBB CO.

DANAHER CORP.

1. HOFFMANN-LA ROCHE LTD.

NOVARTIS AG

SANOFI

SYSMEX CORP.

TAKEDA PHARMACEUTICAL CO. LTD.

List Of Tables

List of Tables

Summary Table : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029

Table 1 : Blood-Related Disorders

Table 2 : Incidence of Blood Cancer Types in U.S., 2023

Table 3 : Total Cost of Care for CLL Patients Treated in the U.S., 2023

Table 4 : Hematology Drugs and their Patent Expiration Dates, 2024

Table 5 : Approved Hematology Drugs, 2023

Table 6 : Clinical Trial Studies on Leukemia, March 2024

Table 7 : Clinical Trial Studies on Lymphoma, March 2024

Table 8 : Clinical Trial Studies on Bleeding Disorders, March 2024

Table 9 : Clinical Trial Studies on Myelofibrosis, March 2024

Table 10 : Clinical Trial Studies on Anemia, March 2024

Table 11 : Clinical Trial Studies on Multiple Myeloma, March 2024

Table 12 : Clinical Trial Studies on Thalassemia, March 2024

Table 13 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 14 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029

Table 15 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 16 : Global Market for Hematology Instruments and Software, by Region, Through 2029

Table 17 : Global Market for Hematology Reagents, by Region, Through 2029

Table 18 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 19 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029

Table 20 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029

Table 21 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029

Table 22 : Global Market for Hematology Drugs, by Region, Through 2029

Table 23 : Global Market for Hematology Drugs, by Drug Type, Through 2029

Table 24 : Drugs Approved for Hematologic Cancers

Table 25 : Global Market for Hematology Oncology Drugs, by Region, Through 2029

Table 26 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029

Table 27 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029

Table 28 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 29 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 30 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 31 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 32 : North American Market for Hematology Drugs, by Drug Type, Through 2029

Table 33 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 34 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 35 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 36 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 37 : European Market for Hematology Drugs, by Drug Type, Through 2029

Table 38 : Incidence of Blood-Related Cancers, by Country, 2022

Table 39 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 40 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 41 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 42 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 43 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029

Table 44 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022

Table 45 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 46 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 47 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 48 : RoW Market for Hematology Drugs, by Drug Type, Through 2029

Table 49 : Revenue Generated by Drugs for Hematology Disorders, 2023

Table 50 : New Developers of Drugs for Hematology Disorders

Table 51 : Report Sources

Table 52 : Abbreviations Used in This Report

Table 53 : Abbott: Company Snapshot

Table 54 : Abbott: Financial Performance, F.Y. 2022 and 2023

Table 55 : Abbott: Product Portfolio

Table 56 : Abbott: News/Key Developments, 2023

Table 57 : Amgen Inc.: Company Snapshot

Table 58 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 59 : Amgen Inc.: Product Portfolio

Table 60 : Amgen Inc.: News/Key Developments, 2021-2024

Table 61 : Bio-Rad Laboratories Inc.: Company Snapshot

Table 62 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023

Table 63 : Bio-Rad Laboratories Inc.: Product Portfolio

Table 64 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023

Table 65 : Bristol Myers Squibb Co.: Company Snapshot

Table 66 : Bristol Myers Squibb Co.: Financial Performance, FY 2022 and 2023

Table 67 : Bristol Myers Squibb Co.: Product Portfolio

Table 68 : Bristol Myers Squibb Co.: News/Key Developments, 2023 and 2024

Table 69 : Danaher Corp.: Company Snapshot

Table 70 : Danaher Corp.: Financial Performance, FY 2022 and 2023

Table 71 : Danaher Corp.: Product Portfolio

Table 72 : Danaher Corp.: News/Key Developments, 2022-2024

Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023

Table 75 : F. Hoffmann-La Roche Ltd: Product Portfolio

Table 76 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024

Table 77 : Novartis AG: Company Snapshot

Table 78 : Novartis AG: Financial Performance, FY 2022 and 2023

Table 79 : Novartis AG: Product Portfolio

Table 80 : Novartis AG: News/Key Developments, 2022

Table 81 : Sanofi: Company Snapshot

Table 82 : Sanofi: Financial Performance, FY 2022 and 2023

Table 83 : Sanofi: Product Portfolio

Table 84 : Sanofi: News/Key Developments, 2023

Table 85 : Sysmex Corp.: Company Snapshot

Table 86 : Sysmex Corp.: Financial Performance, FY 2022 and 2023

Table 87 : Sysmex Corp.: Product Portfolio

Table 88 : Sysmex Corp.: News/Key Developments, 2021-2023

Table 89 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot

Table 90 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022

Table 91 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio

Table 92 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023

List Of Figures

List of Figures

Summary Figure : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029

Figure 1 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders

Figure 2 : Incidence of Blood Cancer Types, by Region, 2022

Figure 3 : Clinical Trial Phases of Drugs for Various Blood-Related Disorders, March 2024

Figure 4 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023

Figure 5 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023

Figure 6 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023

Figure 7 : Global Market Shares of Hematology Drugs, by Drug Type, 2023

Figure 8 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 9 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023

Figure 10 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 11 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 12 : Abbott: Revenue Shares, by Business Unit, F.Y. 2023

Figure 13 : Abbott: Revenue Shares, by Country/Region, FY 2023

Figure 14 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 15 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 16 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 17 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 18 : Bristol Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023

Figure 19 : Bristol Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023

Figure 20 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023

Figure 21 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023

Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023

Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023

Figure 24 : Novartis AG: Revenue Shares, by Business Unit, FY 2023

Figure 25 : Novartis AG: Revenue Shares, by Country/Region, FY 2023

Figure 26 : Sanofi: Revenue Shares, by Business Unit, FY 2023

Figure 27 : Sanofi: Revenue Shares, by Country/Region, FY 2023

Figure 28 : Sysmex Corp.: Revenue Shares, by Business Unit, FY 2023

Figure 29 : Sysmex Corp.: Revenue Shares, by Country/Region, FY 2023

Figure 30 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
• 免疫療法薬の世界市場 2025-11-12
• 農業におけるAIの世界市場 2025-11-10
• 固体酸化物形燃料電池の技術と世界市場 2025-11-07
• 世界の電気アーク炉市場 2025-11-07

BCC Research  出版レポート一覧